Ontak, an interleukin-2- diphtheria toxin fusion protein was FDA-approved for cutaneous T cell lymphoma but has since been discontinued due to production issues. This evidence concerns the gene IL2 and primary cutaneous T-cell non-Hodgkin lymphoma.